

Neuland Laboratories Limited 11th Floor, (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

June 1, 2022

The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai - 400 001

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Mam,

Submission of half yearly disclosure on Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

We refer to our submission of Related Party Transactions pursuant to Regulation 23(9) of SEBI Listing Regulations, 2015 through XBRL on May 20, 2022. Further, as required by you vide your email dated May 27, 2022, please find enclosed herewith the disclosure on Related Party Transactions for the half year ended March 31, 2022.

Request you to treat the above as complied.

HYDERABAD

This is for your information and records.

Thanking you,

Yours sincerely,

For Neuland Laboratories Limited

Sarada Bhamidipati

Company Secretary

Encl: As above

CC: BSE Limited, Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001 Scrip Code: 524558

Neuland Laboratories Limited

Disclosure of Related Party Transactions for the half year ended March 31, 2022

(Rs. lakhs) Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. S.No. Details of the party (listed entity Details of the counterparty In case monies are due to either In case any financial indebtedness is incurred to make or give Details of the loans, inter-corporate deposits, advances or investments /subsidiary) entering into party as a result of the transaction loans, inter-corporate deposits, advances or investments Value of transaction during Type of related party Value of the related party transaction as Relationship of the counterparty Opening balance | Closing balance Nature of indebtedness Cost Tenure Interest Rate Purpose for which the funds will Name enure Secured/ transaction approved by the audit committee the reporting with the listed entity or its (loan/ advance/ inter-corporate (%) be utilised by the ultimate (loan/ issuance of secured period subsidiary debt/ any other etc.) deposit/ investment ecipient of funds (end-usage) Neuland Laboratories Limited Dr. Davuluri Rama Mohan Rao Executive Chairman and KMP As per the Companies Act, 2013 and 230.00 -130.00 Remuneration Shareholders' Approval Neuland Laboratories Limited Mr. Davuluri Sucheth Rao Vice-Chairman & CEO and KMP As per the Companies Act, 2013 and Remuneration 212.50 -1.89 -125.00 Shareholders' Approval Neuland Laboratories Limited Mr. Davuluri Saharsh Rao Vice-Chairman & Managing Director As per the Companies Act, 2013 and Remuneration 212.50 -1.89 -125.00 and KMP Shareholders' Approval Non-Executive Independent Director Sitting fees and 11.40 6.40 -5.00 Neuland Laboratories Limited Mr. Parampally Vasudeva Maiya Non-Executive Independent Director Sitting fees and 13.10 8.10 -5.00 Neuland Laboratories Limited Mr. Humayun Dhanrajgir Commission Non-Executive Independent Director | Sitting fees and 13.10 8.10 -5.00 Mrs. Bharati Rao Neuland Laboratories Limited Commission 13.10 8.10 -5.00 Non-Executive Independent Director Sitting fees and Neuland Laboratories Limited r. Nirmala Murthy 5.50 Non-Executive Independent Director Sitting fees and 10.50 -5.00 Neuland Laboratories Limited Dr. William Gordon Mitchell Commission Non-Executive Non-Independent 11.50 6.50 -5.00 Sitting fees and euland Laboratories Limited Dr. Christopher M Cimarusti Director 13.10 8.10 -5.00 Non-Executive Independent Director Sitting fees and Neuland Laboratories Limited Mr. Homi Rustam Khusrokhan Commission 11 Neuland Laboratories Limited Mr. Deepak Gupta Chief Financial Officer and KMP Remuneration Not Applicable 89.06 12 Neuland Laboratories Limited 13 Neuland Laboratories Limited 14 Neuland Laboratories Limited Mrs. Davuluri Vijaya Rao Relative of Director Office Lease rent 47.29 40.08 -7.21 Mr. Davuluri Sucheth Rao Vice-Chairman & CEO and KMP 63.83 63.83 Office Lease rent Neuland Laboratories Limited Mr. Davuluri Saharsh Rao Vice-Chairman & Managing Director 63.83 63.83 and KMP Vice-Chairman & CEO and KMP Security Deposit given 121.40 Neuland Laboratories Limited Mr. Davuluri Sucheth Rao 121.40 121.40 Vice-Chairman & Managing Director Security Deposit given 121.40 Neuland Laboratories Limited Mr. Davuluri Saharsh Rao 121.40 121.40 and KMP Relative of Promoters Security Deposit given 19.20 Neuland Laboratories Limited Mrs. Davuluri Vijaya Rao 19.20 19.20 18 Neuland Laboratories Limited
19 Neuland Laboratories Limited
19 Neuland Laboratories Limited
19 Neuland Laboratories Limited -404.34 Neuland Laboratories INC Wholly owned subsidiary Business Promotion Not Applicable 393.32 -449.22 Wholly owned subsidiary -133.23 14.79 -77.20 Neuland Laboratories KK Business Promotion Not Applicable 120.92 Neuland Laboratories KK Wholly owned subsidiary Not Applicable 14.79 Advance